AnodyneWiki

Melatonin

Melatonin
Melatonin
Molecular structure drawn from PubChem coordinates
Physical properties
[]
Molecular mass232.28 g/mol [1]
AppearancePale yellow leaflets from benzene [1]
Melting point117 °C [1]
SolubilityIn water, 2 g/L at 20 °C; 5 g/L at 50 °C [1]
Predicted LogP0.8 [1]
Structural Identifiers
[]
Molecular formulaC13H16N2O2
IUPAC nameN-[2-(5-methoxy-1H-indol-3-yl)ethyl]acetamide
SMILESCC(=O)NCCC1=CNC2=C1C=C(C=C2)OC
InChIInChI=1S/C13H16N2O2/c1-9(16)14-6-5-10-8-15-13-4-3-11(17-2)7-12(10)13/h3-4,7-8,15H,5-6H2,1-2H3,(H,14,16)
InChIKeyDRLFMBDRBRZALE-UHFFFAOYSA-N
CAS number73-31-4
UNIIJL5DK93RCL
PubChem CID896
Toxicity
[]
Rat:
- Oral: 3200 mg/kg
 [1]

Melatonin (also known as Melatonine, N-Acetyl-5-methoxytryptamine, Circadin, 5-Methoxy-N-acetyltryptamine, Melatol, N-(2-(5-Methoxy-1H-indol-3-yl)ethyl)acetamide, Melovine, Melapure, Acetamide, N-[2-(5-methoxy-1H-indol-3-yl)ethyl]- or N-[2-(5-methoxyindol-3-yl)ethyl]acetamide) is a depressant and hormone substance of the tryptamine class.

Chemistry

 []

Melatonin is achiral.

Melatonin matches Lipinski's rule of five.

There are currently 9 reagent-interactions on

ReagentColor changeDescription
Marquisno color change
Meckeno color change
Liebermannlight brown
Froehdeno color change
Simon'sno blue color change
Ehrlichreddish > purple
Hofmannyellow / orange > green
Morrispale green
Zimmermannorange

Pharmacology

Mechanism of action []

Melatonin is a derivative of tryptophan. It binds to melatonin receptor type 1A, which then acts on adenylate cylcase and the inhibition of a cAMP signal transduction pathway. Melatonin not only inhibits adenylate cyclase, but it also activates phosphilpase C. This potentiates the release of arachidonate. By binding to melatonin receptors 1 and 2, the downstream signallling cascades have various effects in the body. The melatonin receptors are G protein-coupled receptors and are expressed in various tissues of the body. There are two subtypes of the receptor in humans, melatonin receptor 1 (MT1) and melatonin receptor 2 (MT2). Melatonin and melatonin receptor agonists, on market or in clinical trials, all bind to and activate both receptor types.The binding of the agonists to the receptors has been investigated for over two decades or since 1986. It is somewhat known, but still not fully understood. When melatonin receptor agonists bind to and activate their receptors it causes numerous physiological processes. MT1 receptors are expressed in many regions of the central nervous system (CNS): suprachiasmatic nucleus of the hypothalamus (SNC), hippocampus, substantia nigra, cerebellum, central dopaminergic pathways, ventral tegmental area and nucleus accumbens. MT1 is also expressed in the retina, ovary, testis, mammary gland, coronary circulation and aorta, gallbladder, liver, kidney, skin and the immune system. MT2 receptors are expressed mainly in the CNS, also in the lung, cardiac, coronary and aortic tissue, myometrium and granulosa cells, immune cells, duodenum and adipocytes. The binding of melatonin to melatonin receptors activates a few signaling pathways. MT1 receptor activation inhibits the adenylyl cyclase and its inhibition causes a rippling effect of non activation; starting with decreasing formation of cyclic adenosine monophosphate (cAMP), and then progressing to less protein kinase A (PKA) activity, which in turn hinders the phosphorilation of cAMP responsive element-binding protein (CREB binding protein) into P-CREB. MT1 receptors also activate phospholipase C (PLC), affect ion channels and regulate ion flux inside the cell. The binding of melatonin to MT2 receptors inhibits adenylyl cyclase which decreases the formation of cAMP.[4] As well it hinders guanylyl cyclase and therefore the forming of cyclic guanosine monophosphate (cGMP). Binding to MT2 receptors probably affects PLC which increases protein kinase C (PKC) activity. Activation of the receptor can lead to ion flux inside the cell. [1]

Interactions []

Interaction mechanisms documented in (number of interacting drugs):

inhibition / metabolism41 (1 contraindicated)

Medical side effects []

130 side effects listed on drug labels in (melatonin).

  • Abdominal pain
  • Gastrointestinal pain
  • Aggression
  • Angina pectoris
  • Angioedema
  • Anxiety
  • Arthralgia
  • Musculoskeletal discomfort
  • Arthritis
  • Asthenia
  • Fatigue
  • Back pain
  • Mental disorder
  • Breast disorder
  • Neck pain
  • Chest pain
  • Infection
  • Connective tissue disorder
  • Dermatitis
  • Rash
  • Dizziness
  • Syncope
  • Dyspepsia
  • Eczema
  • Eye disorder
  • Flatulence
  • Gastritis
  • Gastrooesophageal reflux disease
  • Gastrointestinal disorder
  • Glycosuria
  • Breath odour
  • Headache
  • Cardiac disorder
  • Haematuria
  • Herpes zoster
  • Hyperbilirubinaemia
  • Hypersensitivity
  • Hypertension
  • Hypertriglyceridaemia
  • Blood triglycerides increased
  • Hypocalcaemia
  • Hyponatraemia
  • Immune system disorder
  • Libido increased
  • Disturbance in sexual arousal
  • Irritability
  • Lethargy
  • Leukopenia
  • Nail disorder
  • Nasopharyngitis
  • Nausea
  • Nervous system disorder
  • Nervousness
  • Tension
  • Night sweats
  • Nightmare
  • Nocturia
  • Pain
  • Pain in extremity
  • Palpitations
  • Paraesthesia
  • Polyuria
  • Urine output increased
  • Priapism
  • Prostatitis
  • Proteinuria
  • Protein urine present
  • Prurigo
  • Pruritus
  • Psoriasis
  • Restless legs syndrome
  • Salivary hypersecretion
  • Muscle spasms
  • Night cramps
  • Gastric disorder
  • Shock
  • Loss of consciousness
  • Thirst
  • Thrombocytopenia
  • Erythema
  • Urethral disorder
  • Urinary tract disorder
  • Angiopathy
  • Vertigo
  • Vomiting
  • Weight increased
  • Dry mouth
  • Agitation
  • Mood swings
  • Affect lability
  • Stomatitis
  • Mouth ulceration
  • Migraine
  • Tongue disorder
  • Tongue oedema
  • Liver function test abnormal
  • Dry skin
  • Lacrimation increased
  • Gastrointestinal sounds abnormal
  • Malnutrition
  • Skin disorder
  • Abdominal discomfort
  • Gastrointestinal tract irritation
  • Abdominal pain upper
  • Disorientation
  • Disturbance in attention
  • Memory impairment
  • Abnormal dreams
  • Visual acuity reduced
  • Tongue ulceration
  • Galactorrhoea
  • Hepatic enzyme increased
  • Oedema mouth
  • Menopausal symptoms
  • Hot flush
  • Hand dermatitis
  • Hepatobiliary disease
  • Vision blurred
  • Depressed mood
  • Laboratory test abnormal
  • Pruritus generalised
  • Rash generalised
  • Stress
  • Vertigo positional
  • Terminal insomnia
  • Infestation
  • Oral mucosal blistering
  • Dreamy state
  • Insomnia
  • Somnolence

Indications

  • Poor quality sleep
  • Primary insomnia

Subjective effects []

0xea / Melatonin []
Routes:
  • Oral
Effects:
  • improves quality of sleep
Notes:
  • barely effective
a1ko / Melatonin []
Routes:
  • Oral
alina / Melatonin []
Routes:
  • Sublingual
  • Oral (0.5 - 1.8mg)
emily / Melatonin []
Routes:
  • Oral (0.5 - 10mg)
Pilz / Melatonin []
Routes:
  • Oral (0.3 - 100mg)
  • Sublingual (0.5 - 5mg)
  • Rectal (1.5mg)
  • Insufflated (7mg)
Source:
  • German Amazon: Melatonin 0.5mg
  • S3 Chemicals: Melatonin (min. 99%, Food Grade)
  • Polish pharmacy: Melatonin 5mg
  • Italian pharmacy
  • German pharmacy
  • Slovakian pharmacy: Melatonin 3mg
Indication:Effects:Notes:
  • My favorite sleep aid, hangover is non existent and the availability is very good
  • Doses over 0.5mg make no sense
  • Seems to hit harder and faster rectally
  • Ineffective while on stimulants
vivi / Melatonin []
Routes:
  • Oral (1.9mg)

Experience reports

Erowid

There are currently 30 experience reports involving melatonin on : []

Reddit

There are currently 17 trip reports involving melatonin on : []

See also []

External links []

References []

  1. National Center for Biotechnology Information. PubChem Compound Summary for CID 896, Melatonin. Accessed November 20, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/896
  2. U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Melatonin. UNII: JL5DK93RCL. Global Substance Registration System. Accessed November 20, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/JL5DK93RCL

Data sources []

SourceStatusUpdated (UTC)
dosingmissing (no dosing statistics)2026-11-20 06:26:57
drugsprook2026-11-20 06:26:53
erowidok2026-11-20 06:26:55
gsrsok2026-11-20 06:26:53
hmdbmissing (hmdb.ca refused automated access to HMDB0001389)2026-11-20 06:26:53
keggok2026-11-20 06:26:54
pubchemok2026-11-20 06:26:52
redditok2026-11-20 06:26:53
siderok2026-11-20 06:26:53
structureok2026-11-20 06:26:53
wikipediamissing (no Wikipedia article with a drug infobox)2026-11-20 06:26:53